drugset / Trial / NCT07867262
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
RandomizedSequentialOpen-labelTreatment
Summary
The study will evaluate the safety, pharmacokinetics, and preliminary activity of GDC-4198 when given in combination with endocrine therapy (ET) (letrozole, fulvestrant, or giredestrant) as first-line treatment to participants with locally advanced or metastatic Hormone receptor (HR)-positive, Human epidermal growth factor receptor-2 (HER2)-negative breast cancer
Timeline
- Start
- 2026-12-15
- Primary completion
- 2030-08-15
- Completion
- 2030-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | GDC-4198 | Unknown | — | — |
| Subject | Giredestrant | Small molecule | — | — |
| Subject | Letrozole | Other / unclassified | — | — |